Fate Therapeutics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 281.72 million compared to USD 212.15 million a year ago. Basic loss per share from continuing operations was USD 2.91 compared to USD 2.24 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.08 USD | +4.62% | +0.49% | +9.09% |
May. 10 | Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating | MT |
May. 10 | Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.09% | 464M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- FATE Stock
- News Fate Therapeutics, Inc.
- Fate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022